Study Reveals Safety and Quality in CAR T-Cell Therapy Regardless of Center Accreditation

CAR T-Cell Therapy: Bridging the Gap in Access and Outcomes

A recent study has emerged from the Florida Cancer Specialists & Research Institute (FCS) that demonstrates the comparative effectiveness and safety of CAR T-cell therapy, regardless of whether the treatment center holds accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT). This groundbreaking research highlights that patient care location is a significant factor in enhancing patient accessibility and experience in cancer therapy.

The findings, soon to be presented at the 2026 ASCO® Annual Meeting, focus on over 6,800 adult patients diagnosed with diffuse large B-cell lymphoma. These patients were divided into groups based on whether they received CAR T-cell therapy at accredited or non-accredited centers. Key highlights revealed that both groups experienced comparable safety outcomes and there were no notable differences in their time to subsequent treatments.

As Dr. Lucio N. Gordan, President of FCS, noted, "Our research indicates that early safety outcomes were broadly similar between the two types of facilities with no statistically significant variance in post-treatment resource utilization."

The implications of the study are profound, as they challenge the common perception that only accredited centers provide high-quality care. Dr. Ameet Patel, the director of cell therapy at FCS, emphasized the importance of convenience and accessibility: "Patients treated at non-accredited centers achieved results that were comparable to those at accredited facilities. Given the limited number of FACT-accredited centers nationwide, this study is a significant step toward ensuring that patients have access to advanced cancer treatments without the burdensome travel often required to visit accredited locations."

This insight is vital, especially given the complexity and specialization involved in CAR T-cell therapy, which entails using a patient’s own immune cells to combat cancer. A dedicated team is essential throughout the treatment process to monitor the patient closely and offer the best possible outcomes.

For over four decades, FCS has pioneered innovative enhancements in cancer care, characterized by a strong commitment to clinical research and patient outcomes. Their extensive clinical trial programs allow patients access to cutting-edge cancer therapies, further solidifying their standing as a leader in the field amidst private oncology practices in both Florida and the United States. Each year, over 180 active clinical trials are conducted, providing significant contributions to cancer care through those participation experiences.

Thus, as we move forward, the findings from this pivotal study bring to light a critical understanding: that the location of care delivery holds equal weight to the accreditation status when it comes to offering quality cancer treatment. This is particularly encouraging for patients who might find it challenging to travel large distances to accredited centers. By improving access to care, FCS is paving the way for a more patient-centric approach in the landscape of cancer treatment—making high-quality therapies available to those closest to home.

In conclusion, as the healthcare ecosystem continues to evolve, ensuring equitable access to specialized cancer therapies like CAR T-cell treatment can ultimately lead to improved patient experiences and outcomes, irrespective of the accreditation status of the treatment facility.

For more information on how FCS is bringing advanced cancer care closer to communities, visit FLCancer.com.